



TORRENT PHARMACEUTICALS LIMITED

Regd. Office : Torrent House, Off Ashram Road, Ahmedabad-380 009

UNAUDITED CONSOLIDATED FINANCIAL RESULTS

(Rs. in lacs except per share data)

PARTICULARS	UNAUDITED				AUDITED
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31-Dec-2007	31-Dec-2006	31-Dec-2007	31-Dec-2006	31-Mar-2007
Sales (net of Sales Tax / VAT) (see note 4)	34572	33360	101677	95499	129158
Less : Excise and similar duties collected	680	661	1782	2268	2825
Net Sales	33892	32699	99895	93231	126333
Other Operating Income	885	1024	3015	2523	3545
Other Income	67	159	178	167	237
Total Income	34844	33882	103088	95921	130115
Expenditure					
(Increase)/Decrease in Stock in Trade	2773	870	701	(4304)	(4089)
Consumption of Raw/Packing Material	7320	5976	21918	20500	27407
Purchase of Traded Goods	1824	5720	12851	17070	21532
Employees Cost	5668	6067	18158	18714	24884
Research and Development Expenses	2274	1882	7093	5140	7701
Depreciation and Amortization	891	867	2693	2406	3287
Other Expenditure	8826	9212	27058	27521	36870
Total Expenditure	29576	30594	90472	87047	117592
Net Borrowing Costs	505	676	1440	1228	1620
Profit from Ordinary Activities before tax	4763	2612	11176	7646	10903
Tax Expense	1036	47	2151	1173	1552
Net Profit from Ordinary Activities after tax	3727	2565	9025	6473	9351
Paid-up Equity Share Capital (Face Value Rs. 5)	4231	4231	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	-	-	36794
Basic and Diluted EPS for the period	4.40	3.03	10.67	7.65	11.05
Public shareholding					
Number of shares	21922832	-	-	-	21919832
Percentage of shareholding	25.91%	-	-	-	25.91%

Notes

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 31-Jan-08. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended 31-Dec-07. There is no adverse observation in the limited review report on this statement of financial results.
- The figures for the comparative periods have been regrouped, where necessary, to render them comparable with the figures for the current periods.
- The statement of financial results comprise that of the Company and its nine wholly owned subsidiaries. The consolidation of subsidiaries has been done in accordance with Accounting Standard 21 Consolidated Financial Statements issued by the Institute of Chartered Accountant of India.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Rs. in lacs

Particulars	Quarter Ended			Nine Months Ended			Year Ended
	31-Dec-07	31-Dec-06	Growth%	31-Dec-07	31-Dec-06	Growth%	31-Mar-07
(A) Sales in India							
Branded Business	14315	13727	4%	46839	43740	7%	55665
Contract Manufacture	4087	2847	44%	11493	8931	29%	11850
Others	111	53		244	150		168
Total Sales in India	18513	16627	11%	58576	52821	11%	67683
(B) Sales Outside India	16059	16733	-4%	43101	42678	1%	61475
Total Sales (A+B)	34572	33360	4%	101677	95499	6%	129158
Less : Excise and similar duties	680	661		1782	2268		2825
Net Sales	33892	32699	4%	99895	93231	7%	126333

- During the quarter, 3 investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the quarter.
- The standalone audited financial results for the quarter and nine months are available on the Company's website at www.torrentpharma.com.

For **TORRENT PHARMACEUTICALS LIMITED**

sd/-

Place : Ahmedabad
Date : 31-Jan-08

.... Visit us at www.torrentpharma.com....

SUDHIR MEHTA
Chairman